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Abstract
Accumulating evidence over last several years indicates an important role of microglial cells in the
pathogenesis of neuropathic pain. Signal transduction in microglia under chronic pain states has
begun to be revealed. We will review the evidence that p38 MAPK is activated in spinal microglia
after nerve injury and contributes importantly to neuropathic pain development and maintenance.
We will discuss the upstream mechanisms causing p38 activation in spinal microglia after nerve
injury. We will also discuss the downstream mechanisms by which p38 produces inflammatory
mediators. Taken together, current data suggest that p38 plays a critical role in microglial signaling
under neuropathic pain conditions and represents a valuable therapeutic target for neuropathic
pain management.
Background
Injuries of the nervous system, including peripheral nerv-
ous system (PNS, e.g. peripheral nerves, dorsal root gan-
glia, and dorsal roots) and central nervous system (CNS,
e.g. spinal cord and thalamus), often result in neuropathic
pain. These injuries may result from diabetic neuropathy,
viral infection, major surgeries (e.g. amputation, thoracot-
omy), spinal cord injury, and stroke [1-3]. Spontaneous
pain, described as shooting, lancinating or burning pain,
and mechanical allodynia (painful responses to normally
innocuous tactile stimuli) are distinct symptoms of neu-
ropathic pain, although neuropathic pain is also charac-
terized by heat hyperalgesia, mechanical hyperalgesia,
and cold allodynia. Neuropathic pain is a consequence of
neural plasticity, developed both in the PNS (peripheral
sensitization) and CNS (central sensitization). After nerve
injury, neuropathic pain can arise from injury discharge at
the site of axonal injury and ectopic/spontaneous activity
in dorsal root ganglion (DRG) neurons [4-6]. Inflamma-
tory mediators (e.g. cytokines) play a critical role in the
generation of spontaneous activity and neuropathic pain.
Peripheral nerve injury also induces marked phenotypic
changes in DRG neurons [1,2]. While spontaneous activ-
ity from primary afferents drives central sensitization, cen-
tral sensitization is responsible for persistent neuropathic
pain. Central sensitization may also directly drive neuro-
pathic pain in central neuropathic pain conditions caused
by spinal cord injury or stroke. Central sensitization is
induced by enhanced synaptic strength in the spinal cord
and brain regions, due to an increase in excitatory synaptic
transmission (e.g. AMPA and NMDA currents) or/and a
reduction in inhibitory synaptic transmission (e.g. GABA
currents) [7-9]. In addition to increased primary afferent
input, enhanced descending facilitation also contributes
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to spinal neuron hypersensitivity and neuropathic pain
[10,11].
Despite our intensive investigation on neuronal mecha-
nisms of neuropathic pain, current treatment has only
resulted in limited success. Most analgesics are designed
to block neurotransmission, but pain rapidly comes back
after drug effects wear off. This is because many "inflam-
matory mediators (IFMs)" are still produced to activate
nociceptive neurons in the PNS and CNS, causing pain
hypersensitivity. These IFMs include proinflammatory
cytokines [interleukin-1beta (IL-1β), interleukin-6 (IL-6),
and tumor necrosis factor-alpha (TNFα)], prostaglandin
E2 (PGE2), nitric oxide, nerve growth factor, etc. Unlike
neurotransmitters, these IFMs are mainly produced by
non-neuronal cells. The IFMs are produced not only at the
site of nerve injury by Schwann cells, keratinocytes and
immune cells, but also by glial cells in the spinal cord.
Microglia are regarded as a main source of IFMs in the
CNS [12,13]. Although brain-derived neurotrophic factor
(BDNF) is not regarded as an IFM, it is produced by micro-
glia and plays important role in neuropathic pain devel-
opment [14]. Thus our list of IFMs also includes BDNF.
Since IFMs produced by spinal microglia are crucial to the
development of central sensitization and neuropathic
pain (see below), it is extremely important to know how
these IFMs are produced in microglia. We will summarize
the data showing that p38 MAPK is a key regulator of IFM
synthesis and release in microglia and also an essential
contributor to neuropathic pain sensitization.
Microglia and neuropathic pain
Although glial cells were originally regarded as supporting
cells in the CNS, mounting evidence indicates that glia
actively communicate with neurons and contribute
importantly to the development of different types of neu-
rodegenerative diseases. Increasing evidence also suggests
that glial cells in the spinal cord play an important role in
pain facilitation [13,15-17]. For example, peripheral
nerve injury produces profound changes in glial cells
including morphological changes of microglia and astro-
cytes and increased expression of glial markers, such as
CD11b, Iba-1 and GFAP [18]. Glia inhibitors or glia mod-
ifying drugs such as fluorocitrate and propentofylline can
alter pain sensitivity [19-21]. While these early studies are
important to demonstrate an overall role of glia in regu-
lating pain sensitivity, they did not distinguish which type
of glial cells is important in pain regulation.
Among three types of glial cells in the CNS, although oli-
godendrocytes and astrocytes are found in close apposi-
tion to neurons, microglia have gained more attention, in
part because nerve injury-induced microglial changes are
much more robust than that of oligodendrocytes and
astrocytes. A recent microarray study shows that the most
regulated genes following nerve injury are expressed in
spinal microglia [22]. Nerve injury also induces a pro-
found proliferation of spinal microglia [23]. Current stud-
ies on microglial regulation of pain are limited by the lack
of specific markers for microglial activation. CD11b and
Iba-1 are two of the most used markers for demonstrating
microglial activation. However, whether CD11b and Iba-
1 contribute to pain hypersensitivity remains unclear. For-
tunately, nerve injury up regulates the ATP receptor P2X4
and the chemokine receptor CX3CR1 specifically in spinal
microglia, and blocking these receptors results in
decreased neuropathic pain [24-26]. The chemokine
receptor CCR2 and Toll-like receptor-4 are also expressed
in spinal microglia and contribute to neuropathic pain
sensitization [27,28]. Different types of nerve injuries all
induce complement cascade in spinal microglia, and mice
null for C5 terminal complement component exhibit
reduced neuropathic pain sensitivity [22]. Further, mino-
cycline, a microglial inhibitor was shown to prevent or
delay neuropathic pain [29,30]. In particular, intrathecal
injection of ATP-activated microglia induces mechanical
allodynia, indicating that microglial activation is suffi-
cient to induce pain sensitization [24]. Activation of P2X4
receptor is likely to mediate neuropathic pain by produc-
ing BDNF in microglia [14].
Activation of p38 MAPK in spinal microglia and 
neuropathic pain
The mitogen-activated protein kinases (MAPKs) are a fam-
ily of evolutionally conserved molecules that play a criti-
cal role in cell signaling and gene expression. MAPK
family includes three major members: extracellular signal-
regulated kinase (ERK), p38, and c-Jun N-terminal kinase
(JNK), representing three different signaling cascades.
MAPKs are activated by phosphorylation and transduce a
broad range of extracellular stimuli into diverse intracellu-
lar responses by both transcriptional and non-transcrip-
tional regulation. p38 MAPK, which is activated by
upstream kinase MKK3/MMK6, is regarded as a stress-
induced kinase and plays a critical role in inflammatory
responses. p38 inhibitor was shown to effectively alleviate
rheumatoid arthritis and inflammatory pain [31-33].
We used a phosphorylated p38 antibody to examine p38
activation in the rat spinal cord after spinal nerve ligation
(SNL), a commonly used neuropathic pain model [34].
While phsopho-p38 (p-p38) levels are low in non-injured
spinal cord, SNL induces a substantial increase in p-p38
levels in the injured side of the spinal cord (Fig 1a). The
increase in p38 phosphorylation is accompanied by an
increase in p38 activity, as shown by elevated phosphor-
ylation of ATF-2, a substrate of p38 (Fig 1b). Unexpect-
edly, p38 is activated neither in NeuN-expressing neurons
nor in GFAP-expressing astrocytes after SNL. Instead, p38
is activated in spinal cells labeled with microglial markerMolecular Pain 2007, 3:33 http://www.molecularpain.com/content/3/1/33
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CD11b (recognized by OX-42 antibody, Fig 1c–e) [34].
p38 activation in spinal microglia was also reported in the
SNL model by other investigators [35-37], as well as in the
spared nerve injury model [37] taken away [38], after ven-
tral root lesion [39] and spinal cord injury [40]. Apart
from neuropathic pain conditions, microglial activation
of p38 has also been shown in other pain conditions
[41,42].
We have also examined p38 activation at different times
following nerve injury. After SNL, p38 activation in spinal
microglia begins on day one and peaks on day 3. It is note-
worthy that the increase in p-p38 levels is maintained in
spinal microglia even after 3 weeks, despite the fact that at
this late time point p-p38 levels decline from the peak lev-
els [43]. Although most studies confirm a specific micro-
glial activation of p38 in the spinal cord, we do not
exclude the possibility that moderate p38 activation may
also be observed in other spinal cell types when different
species or treatment conditions are tested.
p38 inhibition and neuropathic pain
Mounting evidence indicates that p38 activation plays an
important role in the development of neuropathic pain.
Ligation of L5-spinal nerve (SNL) induces p38 activation in microglial cells in the spinal cord Figure 1
Ligation of L5-spinal nerve (SNL) induces p38 activation in microglial cells in the spinal cord. (a) Immunostaining 
of phosphorylated p38 (p-p38) in the spinal cord 3 days after SNL. Dotted line indicates the outline of the spinal cord gray mat-
ter. Modified from [34]. (b) p38 kinase assay reveals that SNL increases the phosphorylation of the p38 substrate ATF-2, sug-
gesting an increase in p38 activity. To perform kinase assay, p-p38 was first immunoprecipitated with a p-p38 antibody, then 
ATF-2 fusion protein was added. Finally, pATF-2 level was detected using Western blotting with a pATF-2 antibody. (c-e) Dou-
ble immunofluorescence indicates that p-p38 is not colocalized with NeuN, a neuronal marker (c) and GFAP, an astroglial 
marker (d), but colocalized with OX-42 (CD11b), a microglial marker (e). Modified from [34].Molecular Pain 2007, 3:33 http://www.molecularpain.com/content/3/1/33
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Daily administration of the p38 inhibitor SB203580
intrathecally (i.t.) prevents SNL-induced mechanical allo-
dynia [34,35]. p38 inhibitors FR167653 or CNI-1493
(i.t.) also prevents the development neuropathic pain
symptoms in the spared nerve injury model [38] and in a
sciatic inflammatory neuropathy model [44].
Can p38 inhibitor or microglial inhibitor also reverse
established neuropathic pain? This is an extremely impor-
tant question regarding the role of p38 and microglia, and
potential clinical treatment of neuropathic pain with p38
or microglia inhibitors. Early studies showed that
SB203580 cannot reverse neuropathic pain symptoms
when given after nerve injury ref36 taken away [45]. Sim-
ilarly, a microglial inhibitor minocycline was shown to
prevent/delay neuropathic pain, but not to reverse estab-
lished neuropathic pain [29,30]. Minocycline also inhib-
its spinal p38 activation in a neuropathic pain condition
[40]. These data suggest that p38 and microglia are only
important for the induction or development of neuro-
pathic pain, and p38 or microglia inhibitor can only be
used to treat neuropathic pain at early stages, which
would greatly limit the therapeutic potential of p38 and
microglial inhibitors. However, further studies suggest
that inhibition of p38 is also able to reverse neuropathic
pain symptoms in different animal models
[34,38,40,44,46]. Our data show that a single injection of
the p38 inhibitor FR167653 (50 mg/kg, i.p.), 10 days after
SNL, reverses mechanical allodynia for more than 6
hours, with a complete reversal at 3 hours. Further, multi-
ple injections (once every day) of FR167653 persistently
attenuate mechanical allodynia for several days, and pain
attenuation is maintained for additional 2 days after the
last injection (Fig 2a), supporting a role of p38 in the
maintenance of neuropathic pain. Blockade of P2X4 sign-
aling in microglia at 2 weeks after nerve injury can also
reverse neuropathic pain [25]. Recently, a glial modifying
drug propentofylline, given 6 weeks after nerve injury, was
shown to reverse neuropathic pain by inhibiting micro-
glial responses [47].
Nevertheless, the peak activation of p38 and microglia in
the spinal cord occurs in the first several days of nerve
injury, varying from 3 days to 2 weeks due to different
injury conditions [43,48]. After its peak, p38 and micro-
glial activation starts to decrease significantly, although
still maintained at elevated levels at 3 weeks. In contrast,
the peak activation of astrocytes in the spinal cord persists
for a longer period [48]. Therefore, microglia are probably
more important for the early development of neuropathic
(a) Reversal of tactile allodynia by p38 inhibition after spinal nerve ligation (SNL) on mice Figure 2
(a) Reversal of tactile allodynia by p38 inhibition after spinal nerve ligation (SNL) on mice. The p38 inhibitor 
FR167653 was injected (i.p., 50 mg/kg, in 10% DMSO) at 10 days after SNL. The same injection was repeated daily for addi-
tional 4 days (indicated with small arrows). SNL-induced mechanical allodynia was tested at 1 h, 3 h, 6 h, and 1 d after the first 
injection, then daily for another 6 days. Mean ± SEM (n = 5). Note that p38 inhibitor is still effective in reversing neuropathic 
pain. Interestingly, the effect is maintained for 2 more days after the last injection. (b) Inhibition of SNL-induced IL-1β 
upregulation in the spinal cord by p38 inhibition. ELISA shows that intrathecal injection of the p38 inhibitor SB203580 
(10 μg, twice a day for 3 days) reduces SNL-induced IL-1β increase in the L5 spinal cord (dorsal part) 3 days after SNL (L5). **, 
P < 0.01, compared to Sham; +, P < 0.05, compared to SNL, ANOVA.Molecular Pain 2007, 3:33 http://www.molecularpain.com/content/3/1/33
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pain, although they are also involved in the maintenance
of neuropathic pain.
p38 isoforms
There are four different p38 isoforms: α, β, γ and δ. α and
β are two of the major isoforms in the mature nervous sys-
tem [31] and their activated forms are recognized by com-
mercial p-p38 antibodies. While p38α is the most
abundant isoform and expressed in DRG neurons
(unpublished observation), p38β appears to be expressed
in spinal microglia [49]. Current p38 inhibitors are not
isoform-specific due to their design to target common-
ATP binding sites on the kinases and structural similarities
between the p38 isoforms. To explore the distinct role of
p38 isoforms in the development of neuropathic pain, it
is important to specifically inhibit a particular isoform.
More importantly, isoform-specific inhibition will mini-
mize the side effects produced by blocking all p38 iso-
forms with a general inhibitor. Interestingly, it has been
shown that knockdown of p38β but not p38α with anti-
sense oligonucleotides prevents acute pain sensitization
[49]. However, the respective role of p38α and p38β in
chronic pain conditions has not been examined. Also,
therapeutic enthusiasm for antisense oligonucleotides is
not high due to their low efficacy and specificity. A new
strategy, such as RNA interference, may be helpful to
develop potent and selective knock down of a specific iso-
form of p38.
How does peripheral nerve injury activate p38 in spinal 
microglia?
Several studies began to explore the upstream mecha-
nisms causing p38 activation in spinal microglia
[26,36,50,51]. TNFα inhibitor prevents neuropathic pain
development by inhibiting spinal p38 activation [36].
Spinal p38 is activated by intrathecal infusion of IL-1β
and substance P, and p38 inhibitor abolishes the hyperal-
gesia produced by IL-1β and substance P [50,51]. In par-
ticular, recent studies have demonstrated that chemokines
play important roles in mediating neural-glial interaction
and neuropathic pain sensitization. Nerve injury induces
an up-regulation of the chemokine MCP-1 in primary sen-
sory neurons [48,52]. Interestingly, CCR2, one type of
receptors for MCP-1, was expressed in spinal microglia;
spinal p38 activation after nerve injury is reduced in CCR-
2 null mice [27].
Unlike other chemokines that have multiple receptors,
fractalkine (FKN), also called CX3CL1, only has one
known receptor, CX3CR1. It is of great interest that the
CX3CR1 receptor is expressed in spinal microglia and fur-
ther upregulated after nerve injury [25,26]. On the other
hand, FKN is primarily produced in DRG and dorsal horn
neurons [25]. FKN has 2 forms, a membrane-bound form
(large size) and a soluble form (small size) that mediate
cell adhesion and chemotaxis, respectively. FKN is nor-
mally membrane-bound, but this membrane-bound FKN
in the DRG is cleaved after nerve injury, leading to the
release of FKN [26]. A recent study shows that cysteine
protease cathepsin S (CatS), which is produced in micro-
glia after nerve injury, can enhance neuropathic pain by
cleavage of FKN on the membrane of DRG neurons. CatS-
induced hyperalgesia is lost in CX3CR1 null mice [53].
FKN can also be cleaved by metalloproteinases (MMPs),
such as MMP-9 that is released from DRG neurons after
nerve injury (Xu and Ji, unpublished observation).
Intrathecal infusion of FKN not only induces mechanical
allodynia but also activates p38 in spinal microglia [26].
Perfusion of spinal cord slices with FKN activates p38 in
microglia [26]. Conversely, a neutralizing antibody
against CX3CR1 reduces both p38 activation and neuro-
pathic pain [26]. Thus, FKN-CX3CR1-p38 cascade is
required for the development of neuropathic pain.
After peripheral nerve injury, spontaneous activity
(ectopic discharge), which is crucial for the genesis of neu-
ropathic pain, can be recorded in axons as well as in DRG
soma. Is this spontaneous activity required for p38 activa-
tion in spinal microglia? To produce long-term blockade
of nerve activity, we applied bupivacaine microspheres to
the sciatic nerve, which produces a persistent (> 1 week)
conduction blockade due to slow release of bupivacaine
[38]. Using this method for long-term blockade, we found
that spontaneous activity is fully required to initiate p38
activation in spinal microglia. However, nerve conduction
blockade does not reverse p38 activation when applied
after nerve injury [38]. It is suggested that after initiation,
microglia activation could be self-maintained given that
multiple mediators released by microglia can also feed
back to microglia via an autocrine or paracrine fashion.
Since FKN released from neurons triggers microglial acti-
vation, it remains to be tested whether spontaneous activ-
ity after nerve injury can induce the cleavage of FKN.
p38 and microglial signaling
How does p38 activation in spinal microglia result in pain
hypersensitivity? As mentioned above, activated microglia
produce numerous IFMs (e.g., IL-1β, IL-6, TNFα, PGE2,
NO, BDNF), which are also produced in the spinal cord
after nerve injury. All of these IFMs are implicated in pain
facilitation [13-17,44,54,55].
p38 is known to regulate the synthesis of numerous IFMs
via transcriptional regulation [31,32]. For example, SNL-
induced IL-1β up-regulation is attenuated by spinal inhi-
bition of p38 (Fig 2b). Especially, p38 has been shown to
activate the transcription factor NF-κB in cultured micro-
glia [56,57], leading to the expression of the IL-1β, IL-6,
and COX-2 [58]. Interestingly, NF-κB is upregulated in
spinal microglia after nerve injury (unpublished observa-Molecular Pain 2007, 3:33 http://www.molecularpain.com/content/3/1/33
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Schematic representation of signal transduction in spinal microglia after nerve injury Figure 3
Schematic representation of signal transduction in spinal microglia after nerve injury. (a) Activation of microglial 
receptors after nerve injury. Peripheral nerve injury generates spontaneous activity (step-1) leading to the release of chemok-
ines (e.g. MCP-1) from primary sensory DRG neurons (step-2). MCP-1 will activate CCR2 receptors on microglia (step-3). 
Spontaneous activity may also release the proteinases, leading to the cleavage of the chemokine FKN (step-5). After its cleav-
age from the membrane, FKN will be released to bind CX3CR1 receptor on microglia (step-6). Proteinases may also cleave the 
precursors of the cytokines TNFα and IL-1β, leading to the activation of TNFα and IL-1β receptors on microglia (step-7). 
Nerve injury will further release ATP (step-8), activating P2X4 and P2X7 receptors on microglia (step-9). (b) p38 activation in 
spinal microglia and downstream signaling of p38. Activation of GPCR, or cytokine receptors, or P2X receptors results in p38 
MAPK activation in spinal microglia (step-10). p38 activation results in increased expression, through the transcription factor 
NF-κB (step-11) or other transcription factors (e.g. ATF-2), of secreted inflammatory mediators/growth factors (e.g., cytokines 
and BDNF, step-12) or of genes encoding membrane receptors (step-13). In addition, p38 also induces release of PGE2 and IL-
1β via rapid posttranslational regulation (step-14). Upon release, these mediators will sensitize nociceptive dorsal horn neu-
rons via presynaptic and postsynaptic mechanisms, leading to persistent pain hypersensitivity (step-15). Abbreviations used in 
Fig 3: BDNF, brain-derived neurotrophic factor; CatS, cysteine protease cathepsin S; DRG, dorsal root ganglion; FKN, fractalk-
ine; GPCR, G-protein coupled receptor; IL-1β, interleukin-1beta; MAPK, mitogen-activated protein kinase; MAPKAP2: MAPK-
activated protein kinase-2; PLA2, phospholipase A2; TNFα, tumor necrosis factor-alphaMolecular Pain 2007, 3:33 http://www.molecularpain.com/content/3/1/33
Page 7 of 9
(page number not for citation purposes)
tion). Although it was traditionally believed that COX-1 is
constitutively expressed while COX-2 is inducible, COX-1
was shown to be induced in spinal microglia after SNL
[59] and COX-1 inhibitor can attenuate neuropathic pain
[60]. It is worthy to investigate whether p38 is required for
this upregulation. p38 activation after intrathecal IL-1β is
required for the synthesis of iNOS [51]. In addition to p38
activation in spinal microglia, we found that ERK, another
MAPK family member, is also activated in spinal micro-
glia at early times (first several days) of neuropathic pain
development, which is required for neuropathic pain sen-
sitization [61]. p38 and ERK appear to be activated in dif-
ferent populations of spinal microglia. It is likely that the
ERK and p38 pathways can act together to regulate neuro-
pathic pain. For example, a combination of MEK and p38
inhibitors has been shown to suppress endotoxin-induced
expression of iNOS and TNFα in microglia with a much
greater efficacy than each inhibitor alone [62].
p38 can also regulate the synthesis of IFMs by posttransla-
tional regulation. For example, p38 activates phospholi-
pase A2 (PLA2) via its downstream kinase MAPKAP-2
(MAPK activated protein kinase-2). PLA2 plays an impor-
tant role in inflammatory responses. The activation of PLA2
results in the genesis of arachidonic acid for prostaglandin
production, which can be catalyzed via COX to produce
PGE2 [32]. Several PLA2 forms are expressed in spinal cord,
and inhibiting spinal PLA2 induces a potent antihyperalge-
sia [63]. PGE2 release evoked by intrathecal dynorphin
requires spinal p38 activation [64]. p38 activation also
causes a rapid release of IL-1β from spinal microglia. For
example, following application of lipopolysaccharide to an
ex vivo spinal slice preparation, there is a rapid activation of
p38 in spinal microglia and a rapid secretion of IL-1β. Fur-
ther, IL-1β secretion is prevented by p38 inhibitor [65].
Concluding remarks and future directions
In last several years there has been dramatically increasing
interest in studying microglial regulation of neuropathic
pain. We now know that many receptors such as P2X4,
CX3CR1, and CCR2 are specifically expressed or up regu-
lated in spinal microglia after nerve injury or spinal cord
injury, which is essential for neuropathic pain develop-
ment and maintenance. We also know that microglia
enhance pain sensitivity by producing numerous inflam-
matory and pain mediators such as proinflammatory
cytokines and BDNF. However, little is known as to how
activation of these microglial receptors leads to the gener-
ation and release of inflammatory mediators. Many stud-
ies from different laboratories have shown that p38 MAPK
is activated in spinal microglia and contributes to neuro-
pathic pain development/maintenance. p38 stands in a
central place in microglial signaling (Fig 3). First, activa-
tion of multiple microglial receptors can converge on p38
activation. Second, activation of p38 will lead to the syn-
thesis and release of multiple inflammatory mediators.
Therefore, understanding p38 signaling in microglia will
greatly improve our knowledge of microglia-mediated
pain regulation.
Currently, most people use CD11b or IBA-1 as markers for
microglial activation. Although these are specific markers
and show profound changes after injuries, their roles in
neuropathic pain have not been clearly addressed, due to
the lack of specific tools to block the action of these mark-
ers. In several cases, neuropathic pain is dissociated with
CD11b expression [24,66]. Thus additional markers are
needed to demonstrate microglia activation. Phosphor-
ylated MAPKs (e.g. p-p38 or pERK) can be used as extra
markers to reflect the activity of microglia after nerve
injury, because phosphorylation is very rapid and sensi-
tive in response to changes in cellular environment.
Can p38 inhibitors be used to treat clinical pain? Many
pharmaceutical companies have been trying to develop
specific p38 inhibitors. Several p38 MAPK inhibitors
including SB281838, BIRB0796, Ro320-1195, and SCIO-
469 have been tested in clinical trials for inflammatory
diseases such as rheumatoid arthritis as well as for cancer
[67,68]. Given that p38 is a critical contributor in several
chronic pain conditions, p38 inhibitors should also be
tested for clinical pain. A major concern is p38 inhibitors
may produce psychiatric and cardiovascular side effects or
liver toxicity. Development of more specific p38 inhibi-
tors, such as activation status-specific inhibitors and iso-
form-specific inhibitors is highly demanded. Local
delivery of p38 inhibitors or siRNA strategy may also be
considered.
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